SCHEMBL14426571

SCHEMBL14426571

COC(=O)c1ccc(-c2ccc(/C=C3\SC(=O)N(CC(=O)Nc4ccc(C)cc4)C3=O)o2)cc1

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 11/20 0.71
TDP1 Q9NUW8 9/20 0.71
MEN1 O00255 8/20 0.71
POLB P06746 6/20 0.71
PKM P14618 6/20 0.71
L3MBTL1 Q9Y468 3/20 0.71
SMN1; SMN2 Q16637 1/20 0.71
LCK P06239 1/20 0.70
ITGB2 P05107 3/20 0.65
ITGAM P11215 3/20 0.65
MAPT P10636 7/20 0.64
KDM4E B2RXH2 5/20 0.64
APEX1 P27695 4/20 0.64
ALDH1A1 P00352 4/20 0.64
HPGD P15428 2/20 0.64
RECQL P46063 2/20 0.64
PTPN22 Q9Y2R2 2/20 0.64
CTDSP1 Q9GZU7 3/20 0.61
PTGES O14684 1/20 0.61
BLM P54132 5/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14426578 0.88 LCK (0.75) KMT2ATDP1MEN1POLBPKM
SCHEMBL14507110 0.83 KMT2A (1.00) KMT2ATDP1MEN1POLBPKM
SCHEMBL14426567 0.83 KMT2A (1.00) KMT2ATDP1MEN1POLBPKM
SCHEMBL29701306 0.83 KMT2A (1.00) KMT2ATDP1MEN1POLBPKM
SCHEMBL14426456 0.82 LCK (1.00) KMT2ATDP1MEN1POLBPKM
SCHEMBL23662285 0.82 KMT2A (0.69) KMT2ATDP1MEN1POLBPKM
SCHEMBL17387705 0.82 KMT2A (0.74) KMT2ATDP1MEN1POLBPKM
SCHEMBL12094536 0.82 KMT2A (0.74) KMT2ATDP1MEN1POLBPKM
SCHEMBL14426584 0.82 MEN1 (0.74) KMT2ATDP1MEN1POLBPKM
SCHEMBL29441247 0.82 KMT2A (0.74) KMT2ATDP1MEN1POLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070196395-A1 Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-08-23 US disclosed
US-20070196395-A1 Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-08-23 US disclosed
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-05-03 US disclosed
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain UNIVERSITY OF MARYLAND, BALTIMORE 2007-05-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070099970-A1 Immunomodulatory compounds that target and inhibit the pY'binding site of tyrosene kinase p56 LCK SH2 domain LCK, PTPN6, PTPN22 KMT2A 2476/4885TDP1 1445/4885MEN1 4192/4885
US-20070196395-A1 Immunomodulatory compounds that target and inhibit the py'binding site of tyrosene kinase p56 lck sh2 domain LCK, PTPN6, PTPN22 KMT2A 2476/4885TDP1 1445/4885MEN1 4192/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.